Cohort #1 · 2026
Ten scientific ventures from across Europe joined our inaugural cohort — from CO₂-to-bioplastics and clean methane, to precision immunology, protein design and trustworthy AI.
From CO₂ to bioplastics
Turning decarbonation into a real industrial opportunity with genetically-modified photosynthetic microalgae that produce PHA bioplastics directly from CO₂, water and light — targeting price parity with fossil polymers.
Turning CO₂ into clean methane
A proprietary technology that valorises unused CO₂ from biogas plants into clean methane, boosting yields by +60% and unlocking profitability for a €300B European natural gas market.
Carbon capture meets CO₂ mineralization
A new precipitated calcium carbonate (PCC) process combining carbon capture and mineralization — 50% less energy, 65–88% lower environmental impact, engineered from industrial bricks to scale. Targeting cosmetics, paper and paint markets.
Bringing EV therapies from promise to production
HydrOid, a patented bioreactor and process platform for extracellular vesicle therapies — the fastest path to clinical trials, at a fraction of today's cost per dose.
Modeling immunity to make health more predictable
The precision immunology infrastructure layer — a functional immune reference map built on 1,000 deeply profiled European donors and 15 years of multimodal data, to train predictive AI models that de-risk immune drug development.
Where protein design meets reality
A high-throughput protein screening platform built for the AI era — a dense, failure-inclusive Protein Fitness Atlas that turns thousands of in-silico designs into validated products in under two weeks.
Predicting response to immunotherapy
Combining microscopy and AI to directly assess immune cell fitness — a companion diagnostic tackling the biggest immuno-oncology challenge: identifying which patients will actually benefit from checkpoint inhibitors.
A cell-specific strategy to arrest Alzheimer's disease
First-in-class compounds targeting the vulnerability factor that renders neurons susceptible to Alzheimer's pathology — a fundamentally new conceptual approach for a market with no effective treatment.
AI you can actually trust
Verifying LLM reasoning on the fly using formal methods — pioneering trustworthy, deployable generative AI for document and decision logic auditing at scale.
AI-powered football intelligence from a single camera
An end-to-end pipeline that transforms raw monocular video into structured player insights — proprietary motor preference extraction with no multi-camera rigs, addressing a $2.57B multi-sport TAM.
Blue Fellowship